Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
about
Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanismDrug therapy for advanced-stage liver cancerAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaEvolving role of Sorafenib in the management of hepatocellular carcinoma.A long noncoding RNA perturbs the circadian rhythm of hepatoma cells to facilitate hepatocarcinogenesis.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Cancer subclonal genetic architecture as a key to personalized medicine.Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model.HCC therapies--lessons learned.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Novel drugs in clinical development for hepatocellular carcinoma.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Allosteric modulators of MEK1: drug design and discovery.Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells.A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
P2860
Q26775818-330D25E5-6BB4-4023-AD88-C55DCDC6BDFDQ27004410-C22633CD-3AA1-4996-A3FD-CB8D14B3FD02Q28075305-2A649168-6D61-4512-9C6B-3180108B127AQ33779864-3B6151C5-6847-4AE7-910C-A2611302D482Q35024072-0E8390FE-4571-421B-9F7C-4F3F5EC8828CQ35501246-435695ED-B2E8-4B9C-9D9C-CE041C75B3DBQ37448116-AEE58FD5-3297-454F-B5D4-798E592310F3Q37699643-B835E761-AD71-424D-9727-3D547ACE8477Q38184833-379E0DB8-D0BA-4C54-A736-E07B2B4F2B3FQ38444096-6F197E9B-A892-42B1-A015-92AE92E627FFQ38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2BQ38537138-9CFB57A4-AE77-4933-A96E-E911FE598FD3Q38554422-A4138918-B234-4CDF-8CAC-2C17DEEAE4B4Q38635603-4A7A3BD3-2079-4DC4-88F3-C08CBF2E89A0Q38817910-055B78AB-1D43-4208-ABAC-EC1DA1B81988Q42914421-4D585198-728E-4A70-B101-4698F2AB6F83Q46780069-D6BBF709-2315-410A-A5BA-1CEA426A2E94
P2860
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Allosteric MEK1/2 inhibitor re ...... s of hepatocellular carcinoma.
@en
Allosteric MEK1/2 inhibitor refametinib
@nl
type
label
Allosteric MEK1/2 inhibitor re ...... s of hepatocellular carcinoma.
@en
Allosteric MEK1/2 inhibitor refametinib
@nl
prefLabel
Allosteric MEK1/2 inhibitor re ...... s of hepatocellular carcinoma.
@en
Allosteric MEK1/2 inhibitor refametinib
@nl
P2093
P2860
P356
P1433
P1476
Allosteric MEK1/2 inhibitor re ...... s of hepatocellular carcinoma.
@en
P2093
Alex A Adjei
Arne Scholz
Dominik Mumberg
Florian Puehler
Jeffrey N Miner
Karl Ziegelbauer
Maria Kissel
Roberta Schmieder
Roland Neuhaus
P2860
P304
P356
10.1593/NEO.13812
P577
2013-10-01T00:00:00Z